Noul Co., Ltd. (CEO Chan-Yang Lim, hereinafter referred to as Noul) will participate in the '2025 MEDLAB Middle East', a Middle East medical device exhibition held in Dubai from the 3rd to the 6th, and will showcase its AI-based blood and cancer diagnostic solution miLab™, marking the start of its full-scale entry into emerging markets such as the Middle East and Asia.
Medlab Middle East 2025 is the world's largest diagnostics and medical device exhibition, attracting over 800 exhibitors and 30,000 attendees from over 180 countries each year. This international exhibition brings together diagnostic laboratory manufacturers, healthcare professionals, procurement specialists, dealers, and distributors to showcase the latest products and technologies. It also hosts over 150 conferences covering a wide range of diagnostic fields, including diagnostic laboratory management, hematology, histopathology, clinical microbiology, molecular diagnostics, clinical chemistry, and immunology. Noul plans to operate a large booth at Medlab Middle East to directly connect with Middle Eastern customers and strengthen its market presence.
Noul CEO Chan-Yang Lim stated, "Noul has completed preparations for entering the Middle Eastern market, including obtaining approval to sell Class 3 AI medical devices in Saudi Arabia, the largest market in the region with stringent medical device registration procedures. Through this participation in Medlab Middle East, we plan to promote MyLab's key product lines in the Middle Eastern and Asian markets, identify dealers and partners, and actively explore collaboration opportunities with medical institutions in the Middle East."
Reflecting the growing interest in Noul's miLab and its key product lines, over 100 customers and partners visited the Noul booth on the first day of the exhibition alone, with over 40 partnering-related inquiries and meetings. In particular, many customers from key Middle Eastern countries such as Saudi Arabia, the United Arab Emirates, and Kuwait, as well as Asia and Africa, inquired about the introduction of miLab™ BCM, an AI-based blood analysis solution, and miLab™ CER, a cervical cytology solution.
Noul's products that will be fully showcased at the exhibition are miLab™ BCM, an AI-based blood analysis solution, miLab™ CER, an AI-based cervical cytology solution, and miLab™ MAL, an AI-based malaria diagnostic solution. Noul's miLab™ BCM is an innovative product that can replace the peripheral blood smear test (PBS), which is performed over 680 million times worldwide, and is a first-in-class product that covers both large and small diagnostic laboratories. miLab™ CER is an AI-based cervical cytology test (Cytology) product that was recommended for use along with products from global diagnostic companies Roche and Hologic in a 2024 WHO-UNITAID report. miLab™ MAL was introduced as the 'most advanced digital microscopy platform' in a report by the International Pharmaceutical Purchasing Organization (Unitaid) and is highly regarded internationally as a malaria point-of-care diagnostic technology.
Meanwhile, Noul has obtained medical device marketing approval from the Saudi Arabian Food and Drug Authority, the largest market in the Middle East, for 2024. Noul's malaria diagnostic software and cartridges have been approved as Class 3 medical devices, while its blood analysis software and cartridges have been approved as Class 1 medical devices.
- See more related articles
You must be logged in to post a comment.